NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

August 27, 2024

Study Completion Date

September 9, 2024

Conditions

Solid Tumors, AdultSolid TumorMalignant Pleural Mesothelioma (MPM)Epithelioid Hemangioendothelioma (EHE)NF2 Deficient MesotheliomaOther NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion GenesNF2 DeficiencyYAP1 or TAZ Gene Fusions

Interventions

DRUG

IK-930

tablets for oral administration

DRUG

Osimertinib

tablets for oral administration

Trial Locations (12)

3199

Peninsula South Eastern Haematology and Oncology Group (PASO Medical), Frankston

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia

37203

Sarah Cannon Research Institute, Nashville

49546

Start Midwest, Grand Rapids

60637

The University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

78229

Next Oncology, San Antonio

02215

Massachusetts General Hospital, Boston

LE1 5WW

University Hospitals of Leicester NHS Trust, Leicester

SW3 6JJ

The Royal Marsden Hospital, London